Abstract
Buprenorphine is a partial agonist at the μ-opioid receptor with long duration of action and also exhibits delayed antagonist activity. Buprenorphine is finding increasing use as a treatment agent for opioid abuse, though its low efficacy is not well tolerated by all addicts. There is interest in developing a higher efficacy version of buprenorphine and in this mini-review some of the ligands recently discovered, that share with buprenorphine a profile of agonism followed by delayed antagonism, are discussed.
Keywords: opioid ligands, long-term antagonistic activity, opioid abuse, buprenorphine, methadone
Mini-Reviews in Medicinal Chemistry
Title: Opioid Ligands Having Delayed Long-Term Antagonist Activity: Potential Pharmacotherapies for Opioid Abuse
Volume: 3 Issue: 2
Author(s): Stephen M. Husbands and John W. Lewis
Affiliation:
Keywords: opioid ligands, long-term antagonistic activity, opioid abuse, buprenorphine, methadone
Abstract: Buprenorphine is a partial agonist at the μ-opioid receptor with long duration of action and also exhibits delayed antagonist activity. Buprenorphine is finding increasing use as a treatment agent for opioid abuse, though its low efficacy is not well tolerated by all addicts. There is interest in developing a higher efficacy version of buprenorphine and in this mini-review some of the ligands recently discovered, that share with buprenorphine a profile of agonism followed by delayed antagonism, are discussed.
Export Options
About this article
Cite this article as:
Husbands M. Stephen and Lewis W. John, Opioid Ligands Having Delayed Long-Term Antagonist Activity: Potential Pharmacotherapies for Opioid Abuse, Mini-Reviews in Medicinal Chemistry 2003; 3 (2) . https://dx.doi.org/10.2174/1389557033405395
DOI https://dx.doi.org/10.2174/1389557033405395 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation
CNS & Neurological Disorders - Drug Targets Review of Synthesis, Biological Assay and QSAR Studies of β-Secretase Inhibitors
Current Computer-Aided Drug Design Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets The Rheology of Caramel
Current Nutrition & Food Science Getting an Insight into the Complexity of Major Chronic Inflammatory and Degenerative Diseases: A Potential New Systemic Approach to Their Treatment
Current Pharmaceutical Biotechnology Anesthetics as Chemical Tools to Study the Structure and Function of Nicotinic Acetylcholine Receptors
Current Protein & Peptide Science Protein Kinase C Isozyme Selective Peptides - A Current View of What they Tell Us About Location and Function of Isozymes in the Heart
Current Pharmaceutical Design Prenatal Exposure of a Novel Antipsychotic Aripiprazole: Impact on Maternal, Fetal and Postnatal Body Weight Modulation in Rats
Current Drug Safety Structural Modeling Studies of Aldehyde Dehydrogenase X: Insights into Key Interactions in the Tetrameric Assembly of the Isoenzyme
Protein & Peptide Letters Release Characteristics In Vitro and In Vivo of In Situ Gels for a Novel Peptide Compared with Low-Molecular-Weight Hydrophilic Drug
Current Drug Delivery Psychopathological Behaviour and Cognition in Morbid Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial [Hot Topic: Nitric Oxide and Lipoxins: Role in Inflammation and Defence (Guest Editor: Stefano Fiorucci)]
Inflammation & Allergy - Drug Targets (Discontinued) The MT2 Melatonin Receptor Subtype is Present in Human Retina and Decreases in Alzheimers Disease
Current Alzheimer Research Nanoparticle Therapy for Allergic and Inflammatory Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Non-Peptidic GnRH Receptor Antagonists
Current Medicinal Chemistry Biological Basis of Ageing, Age-related Diseases and Interventions
Current Pharmacogenomics and Personalized Medicine Evaluation of Time-Dependent Cytochrome P450 Inhibition in a High-Throughput, Automated Assay: Introducing a Novel Area Under the Curve Shift Approach
Drug Metabolism Letters Meet Our Editorial Board Member
Current Neuropharmacology Serotonin 5-HT<sub>1A</sub> Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs
Current Pharmaceutical Design Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design